Physician

David A Hinchman, MD

According to 2025 Medicare claims, David Hinchman, MD (NPI: 1710914528) practices cardiology in the Boise City, ID market, with the plurality of this provider's patient population coming from Ada, ID. This provider's primary affiliated billing organization is HIGH DESERT HEART & VASCULAR (NPI: 1508552043; TIN: 923461840) and primary practice location at 83642-1224. Hinchman is affiliated with the Trinity Health Integrated Care (ACO ID: A3454), Caravan Collaborative Pathways (ACO ID: A4604), and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Hinchman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 699 traditional Medicare patients, billed 19,320 HCPCS/CPT codes, and received $918,129 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 3,657 prescription claims across 731 beneficiaries totaling $3,418,676 in drug costs, led by Vyndamax (Tafamidis). 2023 DME data shows 11 claims. Open Payments data shows 163 records totaling $211,244. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $121,711 to $918,129. Similarly, Part D prescription costs have moved sharply higher in recent years, from $623,659 to $3,418,676. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,028	3,425	$121,711
2016	2,139	3,605	$127,862
2017	2,258	3,751	$121,609
2018	2,232	3,803	$135,355
2019	2,035	3,201	$100,380
2020	1,729	2,741	$81,233
2021	1,731	2,809	$102,276
2022	1,898	2,971	$98,286
2023	851	1,571	$70,082
2024	699	19,320	$918,129

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	776	5,808	$623,659
2016	813	5,921	$702,228
2017	794	5,129	$731,233
2018	823	5,247	$822,108
2019	881	5,380	$839,981
2020	813	5,036	$932,523
2021	749	4,065	$827,965
2022	798	4,265	$1,295,133
2023	742	3,695	$1,611,733
2024	731	3,657	$3,418,676

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	12	$58
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	11	$425
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	244	252	$132
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	270	434	$90
93015	Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician	409	432	$49
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	290	314	$9
J2785	Injection, regadenoson, 0.1 mg	369	1,552	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	47	1,530	$1,283,998
Camzyos	Mavacamten	127	3,995	$1,064,613
Jardiance	Empagliflozin	312	19,656	$369,911
Farxiga	Dapagliflozin Propanediol	402	17,682	$317,776
Eliquis	Apixaban	105	7,412	$144,453

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	158	$88,567	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	5	$122,677	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David A. Hinchman, MD?

Tedicare shows public-source Medicare data for David A. Hinchman, MD (NPI 1710914528), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David A. Hinchman, MD have ACO affiliation data?

David A. Hinchman, MD is shown with ACO affiliation data for Trinity Health Integrated Care (MSSP, ACO ID A3454), Caravan Collaborative Pathways (MSSP, ACO ID A4604), and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to David A. Hinchman, MD?

David A. Hinchman, MD is linked to HIGH DESERT HEART & VASCULAR (billing NPI 1508552043) in the available physician profile data.

Does David A. Hinchman, MD have Open Payments data?

David A. Hinchman, MD has 163 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.